Beckman Coulter, a global life sciences company with quarterly revenues of more than $800 million, is moving more work to Indianapolis along with 100 jobs.

The Fullerton, Calif.-based company, whose two Pike Township facilities already employ more than 400, said today it will will relocate its precision plastics injection molding operation to the Park 100 business park on the Indianapolis Northwestside.

Beckman Coulter’s expansion comes two years after it said it would relocate its centrifuge development and manufacturing operation from Palo Alto, Calif., to Indianapolis. Beckman Coulter has been in Indianapolis since acquiring a locally based high-tech start-up in December 1996.

The Indiana Economic Development Corp., a board led by Gov. Mitch Daniels, will give Beckman Coulter up to $830,000 in performance-based tax credits and up to $450,000 in training grants based on the company’s job creation plans. The city of Indianapolis and Indianapolis Economic Development Inc. will support additional incentives.

Daniels and Indianapolis Mayor Greg Ballard were on hand for the job news.

“Our operation in Indianapolis has become a center of excellence for Beckman Coulter. The area offers a favorable business environment and lower total cost of operations, plus a local workforce with strong skills in both engineering and manufacturing,” said Scott Atkin, a vice president with Beckman Coulter. “The state of Indiana’s strategic intent to focus on life sciences and advanced manufacturing aligns nicely with our business objectives.”

Founded in 1935, Beckman Coulter manufactures and markets diagnostic test systems composed of instruments, consumables, service and data management tools, according to Morningstar financial resource.

The majority of sales are to clinical laboratories. The company employs 11,000, Morningstar says.

Beckman Coulter reported in late October that third-quarter earnings tumbled 94 percent as restructuring and acquisition costs masked higher sales and margins.

The company said net earnings plunged to $1.5 million, or 2 cents per share, from $24.1 million, or 37 cents per share, during the same period year prior. Revenue rose 8 percent to $822.8 million from $758.8 million.

Excluding costs for the $780 million buyout of Olympus’ diagnostics unit, the company said it earned 85 cents per share. Analysts polled by Thomson Reuters expected profit of 84 cents per share on revenue of $819.1 million.

IndyStar.com markets: Beckman Coulter